MAP3K14

Mitogen-activated protein kinase kinase kinase 14

25,761 patent compounds predicted against MAP3K14, 13,155 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1613689	0.72	20/20
SCHEMBL1612839	0.69	20/20
SCHEMBL1613461	0.68	20/20
SCHEMBL1613463	0.68	20/20
SCHEMBL1613687	0.68	20/20
SCHEMBL1613361	0.67	20/20
SCHEMBL1485427	0.64	20/20
SCHEMBL1614897	0.64	20/20
SCHEMBL1614900	0.64	20/20
SCHEMBL1485070	0.61	20/20
SCHEMBL1611749	0.61	20/20
SCHEMBL1612311	0.59	20/20
SCHEMBL1612312	0.59	20/20
SCHEMBL1613896	0.58	20/20
SCHEMBL1612748	0.58	20/20
SCHEMBL1612870	0.58	20/20
SCHEMBL1613384	0.58	20/20
SCHEMBL1485171	0.57	20/20
SCHEMBL1484994	0.55	20/20
SCHEMBL1485258	0.55	20/20

Germline variants in MAP3K14 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAP3K14 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAP3K14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE2	COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K14 binder may also engage these)

Protein	Name	Similarity
Q9WUL6	—	1.000	Q9WUL6 →
Q8BLR5	—	0.995	Q8BLR5 →
Q0KK55	—	0.994	Q0KK55 →
P0C6A0	—	0.991	P0C6A0 →
Q3UIZ8	—	0.990	Q3UIZ8 →
B1ASB6	—	0.990	B1ASB6 →
Q6PAC4	—	0.990	Q6PAC4 →
Q8NDX1	—	0.990	Q8NDX1 →
B2RXH4	—	0.990	B2RXH4 →
Q0VET5	—	0.990	Q0VET5 →
Q8BG34	—	0.990	Q8BG34 →
Q8BZW2	—	0.989	Q8BZW2 →
Q05AH6	—	0.989	Q05AH6 →
A6NGG8	—	0.989	A6NGG8 →
Q76I79	—	0.989	Q76I79 →
Q8BWG4	—	0.989	Q8BWG4 →
Q8BP99	—	0.989	Q8BP99 →
Q96PX9	—	0.989	Q96PX9 →
Q8VDG6	—	0.989	Q8VDG6 →
Q86YN6	—	0.988	Q86YN6 →
A0A0A6YY25	—	0.988	A0A0A6YY25 →
Q0GGX2	—	0.988	Q0GGX2 →
Q8NHY3	—	0.988	Q8NHY3 →
Q9Z0E3	—	0.988	Q9Z0E3 →
Q8IYX3	—	0.988	Q8IYX3 →
Q9UFD9	—	0.988	Q9UFD9 →
Q4R736	—	0.988	Q4R736 →
Q63572	—	0.988	Q63572 →
A6NJZ7	—	0.988	A6NJZ7 →
Q9BSI4	—	0.988	Q9BSI4 →